Coloplast cuts annual organic revenue growth outlook through 2030 to 5-7% from 7-8%

• Coloplast cut its annual organic revenue growth ambition through FY 2029/30 to 5-7% from 7-8%.
• The revised outlook targets a constant-currency EBIT margin in the mid-20% range, with ROIC around 20%, previously above 20%.
• For FY 2026/27, organic revenue growth is forecast at 5-7%; constant-currency EBIT margin before special items is expected around 25%.
• The downgrade reflects US biologics reimbursement changes, healthcare pricing pressure, inflation and increased investment in innovation and selected commercial areas.
• A cost-saving program aims to free up around DKK 500 million, reaching full impact in FY 2027/28.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coloplast A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611021119OMX_____CNEWS_EN_GNW1001301348_en) on November 02, 2026, and is solely responsible for the information contained therein.